Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis

Genes Chromosomes and Cancer

Volumn 55, Issue 10, 2016, Pages 741-749

  Luchini, Claudio ^a,b   Veronese, Nicola ^c,d   Yachida, Shinichi ^e   Cheng, Liang ^f   Nottegar, Alessia ^a   Stubbs, Brendon ^g   Solmi, Marco ^c,d   Capelli, Paola ^a   Pea, Antonio ^a   Barbareschi, Mattia ^b   Fassan, Matteo ^c   Wood, Laura D ^h   Scarpa, Aldo ^a  

^a UNIVERSITY AND HOSPITAL TRUST OF VERONA   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d Institute of Clinical Research and Education in Medicine (IREM)   (Italy)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN;

CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; COLORECTAL CARCINOMA; FOLLOW UP; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; MESOTHELIOMA; META ANALYSIS (TOPIC); NEOPLASM; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84981277931     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22381     Document Type: Review

References (51)

1. Andrici J, Goeppert B, Sioson L, Clarkson A, Renner M, Stenzinger A, Tayao M, Watson N, Farzin M, Toon CW, Smith RC, Mittal A, Samra JS, Hugh TJ, Chou A, Lawlor RT, Weichert W, Schirmacher P, Sperandio N, Ruzzenente A, Scarpa A, Gill AJ. 2016. Loss of BAP1 expression occurs frequently in intrahepatic cholangiocarcinoma. Medicine 95:e2491.
2. Andrici J, Parkhill TR, Jung J, Wardell KL, Verdonk B, Singh A, Sioson L, Clarkson A, Watson N, Sheen A, Farzin M, Toon CW, Gill AJ. 2016. Loss of expression of BAP1 is very rare in non-small cell lung carcinoma. Pathology 48:336–340.
3. Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH. 2014. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathol Oncol Res 20:145–151.
4. Battaglia A. 2014. The importance of multidisciplinary approach in early detection of bap1 tumor predisposition syndrome: Clinical management and risk assessment. Clin Med Insights Oncol 8:37–47.
5. Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, Yang H, Carbone M. 2015. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36:76–81.
6. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M. 2011. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43:668–672.
7. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. 2013. BAP1 and cancer. Nat Rev Cancer 13:153–159.
8. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, Janku F, Crane CH, Mishra L, Vauthey JN, Wolff RA, Mills G, Javle M. 2014. Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications. PLoS One 9:e115383.
9. Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G, Murer B, Barbareschi M, Giuliani S, Cavazza A, Marchetti G, Vermi W, Facchetti F. 2015. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol 28:1043–1057.
10. Daou S, Hammond-Martel I, Mashtalir N, Barbour H, Gagnon J, Iannantuono NV, Nkwe NS, Motorina A, Pak H, Yu H, Wurtele H, Milot E, Mallette FA, Carbone M, Affar el B. 2015. The BAP1/ASXL2 histone H2A deubiquitinase complex regulates cell proliferation and is disrupted in cancer. J Biol Chem 290:28643–28663.
11. DerSimonian R, Laird N. 1986. Meta-analysis in clinical trials. Control Clin Trials 7:177–188.
12. Duval S, Tweedie R. 2000. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463.
13. Egger M, Davey Smith G, Schneider M, Minder C. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634.
14. Eletr ZM, Wilkinson KD. 2011. An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys 60:3–11.
15. Fan LH, Tang LN, Yue L, Yang Y, Gao ZL, Shen Z. 2012. BAP1 is a good prognostic factor in advanced non-small cell lung cancer. Clin Invest Med 35:E182–E189.
16. Farzin M, Toon CW, Clarkson A, Sioson L, Watson N, Andrici J, Gill AJ. 2015. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology 47:302–307.
17. Gossage L, Murtaza M, Slatter AF, Lichtenstein CP, Warren A, Haynes B, Marass F, Roberts I, Shanahan SJ, Claas A, Dunham A, May AP, Rosenfeld N, Forshew T, Eisen T. 2014. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 53:38–51.
18. Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, Voss MH, Motzer RJ, Coleman JA, Cheng EH, Russo P, Hsieh JJ. 2013. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 63:848–854.
19. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM. 2010. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330:1410–1413.
20. Higgins JP, Thompson SG. 2002. Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558.
21. Ismail IH, Davidson R, Gagné JP, Xu ZZ, Poirier GG, Hendzel MJ. 2014. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res 74:4282–4294.
22. Je EM, Lee SH, Yoo NJ. 2012. Somatic mutation of a tumor suppressor gene BAP1 is rare in breast, prostate, gastric and colorectal cancers. Apmis 120:855–856.
23. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, Barlev N, Berger SL, Prendergast GC, Rauscher FJ. 3rd. 1998. BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16:1097–1112.
24. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, Tortora G, de Braud F, Scarpa A, Jarnagin W, Klimstra D, Karchin R, Velculescu VE, Hruban RH, Vogelstein B, Kinzler KW, Papadopoulos N, Wood LD. 2013. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 45:1470–1473.
25. Joseph RW, Kapur P, Serie DJ, Eckel-Passow JE, Parasramka M, Ho T, Cheville JC, Frenkel E, Rakheja D, Brugarolas J, Parker A. 2014. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer 120:1059–1067.
26. Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, Frenkel E, Parker AS, Brugarolas J. 2016. Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. J Urol 195:180–187.
27. Kalirai H, Dodson A, Faqir S, Damato BE, Coupland SE. 2014. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. Br J Cancer 111:1373–1380.
28. Kapur P, Christie A, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, Shariat SF, Bensalah K, Rioux-Leclercq N, Xie XJ, Lotan Y, Margulis V, Brugarolas J. 2014. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. J Urol 191:603–610.
29. Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. 2013. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation. Lancet Oncol 14:159–167.
30. Koopmans AE, Verdijk RM, Brouwer RW, van den Bosch TP, van den Berg MM, Vaarwater J, Kockx CE, Paridaens D, Naus NC, Nellist M, van IJcken WF, Kiliç E, de Klein A. 2014. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol 27:1321–1330.
31. Kumar R, Taylor M, Miao B, Ji Z, Njauw JC, Jönsson G, Frederick DT, Tsao H. 2015. BAP1 has a survival role in cutaneous melanoma. J Invest Dermatol 135:1089–1097.
32. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 339:b2700.
33. Luchini C, Capelli P, Fassan M, Simbolo M, Mafficini A, Pedica F, Ruzzenente A, Guglielmi A, Corbo V, Scarpa A. 2014. Next generation histopathologic diagnosis: A lesson from a hepatic carcinosarcoma. J Clin Oncol 32:e63–e66.
34. Luchini C, Veronese N, Solmi M, Cho H, Kim JH, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, Nakayama K, Kyo S, Lee SY, Kim DW, Yousef GM, Scorilas A, Nelson GS, Köbel M, Kalloger SE, Schaeffer DF, Yan HB, Liu F, Yokoyama Y, Zhang X, Pang D, Lichner Z, Sergi G, Manzato E, Capelli P, Wood LD, Scarpa A, Correll CU. 2015. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: A systematic review and meta-analysis. Oncotarget 6:39088–39097.
35. Luchini C, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, Veronese N. 2016. Extra-nodal extension is an important prognostic parameter for both colonic and rectal cancer. Ann Oncol 27:955–956.
36. Luchini C, Nottegar A, Solmi M, Sergi G, Manzato E, Capelli P, Scarpa A, Veronse N. 2016. Prognostic implications of extra-nodal extension in node-positive squamous cell carcinoma of the vulva: A systematic review and meta-analysis. Surg Oncol 25:60–65.
37. Luchini C, Veronese N, Pea A, Sergi G, Manzato E, Nottegar A, Solmi M, Capelli P, Scarpa A. 2016. Extra-nodal extension in N1-adenocarcinoma of pancreas and papilla of Vater: A systematic review and meta-analysis of its prognostic significance. Eur J Gastroenterol Hepatol 28:205–209.
38. Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, Fukuda M, Ohta T. 2009. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res 69:111–119.
39. Nottegar A, Veronese N, Solmi M, Luchini C. 2016. Tumor suppressor gene ARID1A in cancer: Recent advances and future perspective. J Carinog Mutagene 7:255.
40. Shah AA, Bourne TD, Murali R. 2013. BAP1 protein loss by immunohistochemistry: A potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology 45:651–656.
41. Simbolo M, Fassan M, Mafficini A, Lawlor RT, Ruzzenente A, Scarpa A. 2016. New genomic landscapes and therapeutic targets for biliary tract cancers. Front Biosci 21:707–718.
42. Simbolo M, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, Melisi D, Malleo G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C, Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, de Braud F, Scarpa A. 2014. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 5:2839–2852.
43. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. 2000. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012.
44. Tang J, Xi S, Wang G, Wang B, Yan S, Wu Y, Sang Y, Wu W, Zhang R, Kang T. 2013. Prognostic significance of BRCA1-associated protein 1 in colorectal cancer. Med Oncol 30:541.
45. van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, Kroes WG, Ruivenkamp CA, Shukla S, de Klein A, Kiliç E, Harbour JW, Luyten GP, van der Velden PA, Verdijk RM, Jager MJ. 2014. Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol 98:1738–1743.
46. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, Wilkinson KD. 2008. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 68:695369–62.
47. Veronese N, Luchini C, Nottegar A, Kaneko T, Sergi G, Manzato E, Solmi M, Scarpa A. 2015. Prognostic impact and implications of extra-nodal extension in lymph-node positive thyroid cancers: A systematic review and meta-analysis. J Surg Oncol 112:828–833.
48. Veronese N, Nottegar A, Pea A, Solmi M, Stubbs B, Capelli P, Sergi G, Manzato E, Fassan M, Wood LD, Scarpa A, Luchini C. 2016. Prognostic impact and implications of extra-capsular lymph node involvement in colorectal cancer: A systematic review with meta-analysis. Ann Oncol 27:42–48.
49. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. 2015. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed on 10/13/2015.
50. Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, Tan Y, Menges CW, Cai KQ, Litwin S, Peng H, Karar J, Rauscher FJ, Testa JR. 2014. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res 74:4388–4397.
51. Zauderer MG, Bott M, McMillan R, Sima CS, Rusch V, Krug LM, Ladanyi M. 2013. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J Thorac Oncol 8:1430–1433.